Arun S. Menawat - 15 May 2025 Form 4 Insider Report for Profound Medical Corp. (PROF)

Reporting relationship: CEO, Director
Issuer ticker: PROF
Reported as of: 15 May 2025
Net transaction value: +$100,151
SEC form: 4
Accepted by SEC: 20 May 2025, 13:56:42 UTC
Prior SEC filing: 12 Mar 2025
Next SEC filing: 20 May 2025
Source filing: View source filing
Reporting owner signature: /s/ Arun Menawat

Key filing fact

Arun S. Menawat filed Form 4 for Profound Medical Corp. (PROF) on 20 May 2025.

Key facts

This page summarizes Arun S. Menawat's Form 4 filing for Profound Medical Corp. (PROF).
2 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 20 May 2025, 13:56.

Change

Previous filing in this sequence was filed on 12 Mar 2025.
Current net transaction value: +$100,151.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001685893 Primary reporting owner

Menawat Arun Swarup

Relationship: CEO, Director
Address: C/O PROFOUND MEDICAL CORP., 2400 SKYMARK AVENUE, UNIT 6, MISSISSAUGA, ONTARIO, CANADA
Signature: /s/ Arun Menawat
Signature date: 20 May 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

PROF transaction

Common Shares

Purchase

Transaction value: $43,263
Shares: +10,003
Change %: +1.8%
Price: $4.32
Shares after: 575,062
Date: 15 May 2025
Ownership: Direct
Footnotes: F1

PROF transaction

Common Shares

Purchase

Transaction value: $56,888
Shares: +12,027
Change %: +2.1%
Price: $4.73
Shares after: 587,089
Date: 16 May 2025
Ownership: Direct
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.30 to $4.35, inclusive. The reporting person undertakes to provide to Profound Medical Corp., any security holder of Profound Medical Corp., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4.

Footnote F2

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.70 to $4.78, inclusive. The reporting person undertakes to provide to Profound Medical Corp., any security holder of Profound Medical Corp., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (2) to this Form 4.

SEC remarks

As a foreign private issuer, Profound Medical Corp. securities are currently exempt from Section 16 pursuant to Rule 3a12-3(b) of the Exchange Act. As such, this is an informational and voluntary report which shall not be deemed an admission that, as of the date hereof, the filing person is required to report changes in beneficial ownership of Profound Medical Corp. securities registered under Section 12 of the Exchange Act.